Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging

Read More

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals

Read More

Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects

Read More

Recent Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range